Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 2, 2011, Pages 423-428

  Thomas, Saji ^a   Mathela, Chandra S ^b   Agarwal, Ashutosh ^a   Paul, Saroj Kumar ^a  

^a Jubilant Life Sciences Ltd   (India)

^b KUMAUN UNIVERSITY   (India)

Author keywords

Carbamazepine; Elemental analysis; Impurity; LC MS MS; NMR

Indexed keywords

AMIDE; CARBAMAZEPINE; CARBON; HYDROGEN; NITROGEN; SULFUR; TETRABENZO[B,F,B'F']AZEPINO[4',5':4,5]THIENO[2,3 D]AZEPINE 3,9 DICARBOXAMIDE; UNCLASSIFIED DRUG;

ARTICLE; DRUG IMPURITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; ION TRAP MASS SPECTROMETRY; ISOLATION PROCEDURE; LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANTICONVULSANTS; CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; DRUG CONTAMINATION; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TANDEM MASS SPECTROMETRY; TECHNOLOGY, PHARMACEUTICAL;

EID: 79960035630     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.05.030     Document Type: Article

References (16)

1. Martindale - The Complete Drug Reference 2009, 471-477. Royal Pharmaceutical Society of Great Britain. thirty sixth ed. J.E.F. Reynolds (Ed.).
2. Evans R.W., Clay T.H., Gualtieri C.T. Carbamazepine in pediatric psychiatry. J. Am. Acad. Child Adolesc. Psychiatry 1987, 26:2-8.
3. Liu H., Delgado M.R. Effect of valproate and falbamate on carbamazepine and its metabolites in epileptic children. J. Epilepsy 1997, 10:37-41.
4. United States Pharmacopoeia-32 2009, vol. 2. pp. 1784-1785.
5. European Pharmacopoeia 2008, vol. 2. pp. 1411-1412. sixth ed.
6. British Pharmacopoeia 2008, vol. 1. pp. 384-385.
7. Indian Pharmacopoeia 2010, vol. 2. pp. 977-978.
8. 2 treatment of antiepileptic drug carbamazepine. Chemosphere 2004, 54:497-505.
9. Sheldon E.M., Downar J.B. Development and validation of a single robust HPLC method for the characterization of a pharmaceutical starting material and impurities from three suppliers using three separate synthetic routes. J. Pharm. Biomed. Anal. 2000, 23:561-572.
10. ICH Guidelines, Impurities in New Drug Substances Q3A (R2), October 25, 2006.
11. W. Schindler, Riehen, Geigy Chemical Corporation, United States Patent US 2,948,718 (1960).
12. G. Acklin, E. Aufderhaar, G. Kaupp, B. Raz, Ciba-Geigy Chemical Corporation, United States Patent US 4,847,374 (1989).
13. K.D. Vyas, W.S. Jafri, A.K. Kulkarni, Max India Limited, United States Patent US 6,224,908 B1 (2001).
14. Urrea E.M., Radjenovic J., Caminal G., Petrovic M., Vicent T., Barcelo D. Oxidation of atenolol, propranolol, carbamazepine and clofibric acid by a biological fenton-like system mediated by the white-rot fungs Trametes versicolor. Water Res. 2010, 44:521-532.
15. Kricka L.J., Ledwith A. Dibenz[b,f]azepine and related ring systems. Chem. Rev. 1974, 74:101-123.
16. 13C NMR studies on dienz[b,f]azepines. J. Heterocycl. Chem. 1983, 20:109-112.